User login

Enter your username and password here in order to log in on the website:
Choose language: English | Deutsch

Infront up-to-date–
news, dates, events

News

Events

Title
Date
Location
Category
FIX EMEA Trading Conference 2020
18.09.2020
London
Exhibitions and Congresses

The EMEA Trading Conferenceis Europe’s largest one-day electronic trading event. The event will cover the most pressing issues facing the institutional trading community and provide a neutral platform for buy-side, sell-side, exchanges, vendors and regulators to share their ideas on how the community can continue to collaborate. Designed to appeal to all asset classes, the agenda will maintain a great balance of topics across multiple asset classes.

Our colleagues Ricky Strachan, Ken Riggio and Richard Burtsal are looking forward to meeting you at booth D7!

19th COPS Usertreff
22.10.2020
Rust
Exhibitions and Congresses

As in previous years, COPS invites to their annual COPS user meeting this year from 22 to 23 October 2020 at the Seehotel Rust in Rust on Neusiedlersee.

The customers can expect a versatile and varied program, ranging from innovations in software solutions, successful project reports to practical application examples.

As a strategic partner, COPS gives us the opportunity to present our company and our solutions and show-case the cooperation with COPS.

On site, our colleagues Catherine Hanek, Achim Beisswenger and Sebastian Ullrich will be available for a lively exchange of ideas.

You can find further information here...

SIPUGday 2020
27.10.2020
Zurich
Exhibitions and Congresses

The SIPUGday focuses since the start on market data and related technologies, services and products in the front, back and middle office. Regulations and their impact on data are also a topic for our audience.

Infront and vwd will be represented on site by Ivo Bieri, Managing Director Switzerland. He will be happy to inform you about the advantages for you of the merger of the two companies in the future. We look forward to a lively exchange with you!


Date
October 27, 2020
 

Place
Marriott Hotel,
Neumühlequai 42
8006 Zurich

Read more...

DKF 2020, 10. D-A-CH Kongress für Finanzinformationen
02.12.2020
Munich
Exhibitions and Congresses

We will again be represented at the DKF this year and look forward to your visit to our stand.

Further information will be available here soon or on the official DKF 2020 website.

 Latest news on markets, economy and companies

Newsroom

Business Wire

Mynewsdesk

GlobeNewswire

20.05.2020 GlobeNewswire: Idorsia platziert erfolgreich neue Aktien und sichert damit die langfristige Finanzierung des Wachstumsplans des Unternehmens

Idorsia platziert erfolgreich neue Aktien und sichert damit die langfristige

Finanzierung des Wachstumsplans des Unternehmens

 

• Idorsia platziert erfolgreich 11 Millionen neue Aktien und erzielt

einen Bruttoerlös von CHF 330 Millionen

 

Allschwil, Schweiz – 20. Mai 2020

Idorsia Ltd (SIX: IDIA, “Idorsia”) gab heute bekannt, dass erfolgreich 11

Millionen neue Aktien (die “platzierten Aktien”) mittels Accelerated

Bookbuilding-Verfahren platziert wurden, wobei die platzierten Aktien 8,4% des

aktuell ausgegebenen Aktienkapitals von Idorsia entsprechen. Der durch das

Angebot erzielte Nettoerlös dient Idorsia primär zur Vorbereitung des

Markeintritts des ersten kommerziellen Produkts sowie zur weiteren Finanzierung

der Entwicklung der attraktiven und sich im Spätstadium befindenden Pipeline

Kandidaten, darunter Aprocitentan, Clazosentan und Lucerastat, sowie der

diversifizierten Pipeline in der Frühphase und der Präklinik.

 

André C. Muller, Chief Financial Officer, kommentierte:

“Ich bin sehr zufrieden mit der Art und Weise, wie diese Runde der

Mittelbeschaffung verlaufen ist, soweit, dass wir den angebotenen Betrag erhöht

haben. Wir haben eine grosse Nachfrage an den neu geschaffenen Aktien durch

qualitative hochstehende Anleger erhalten. Diese fokusieren sich auf echte

Wertschöpfung und glauben an unsere langfristige Strategie, der Investition in

eine breite Pipeline innovativer Medikamente.”

 

Idorsia platzierte erfolgreich 11 Millionen neue Namenaktien mit einem

Nennwert von je CHF 0.05 zu CHF 30 je neuer Aktie (der “Angebotspreis”). Die

platzierten Aktien, welche 8,4% des aktuell ausgegeben Aktienkapitals von

Idorsia entsprechen, stammen aus dem bestehenden genehmigten Kapital von

Idorsia; das Bezugsrecht der bestehenden Aktionäre wurde ausgeschlossen. Es

wird erwartet, dass die platzierten Aktien am oder um den 22. Mai 2020 gemäss

dem International Reporting Standard der SIX Swiss Exchange kotiert und zum

Handel zugelassen werden. Die platzierten Aktien sind den bestehenden Aktien

gleichgestellt.

 

Idorsia hat im Zusammenhang mit der Platzierung der Aktien einer 90-tägigen

Lock-up-Periode zugestimmt. Jean-Paul und Martine Clozel, die Hauptaktionäre

von Idorsia, haben 28,4% der platzierten Aktien zum Angebotspreis erworben und

erhalten damit ihre bisherige Beteiligung aufrecht. Sie haben einer 180-tägigen

Lock-up-Periode ab dem Zeitpunkt der Kotierung der platzierten Aktien

zugestimmt, welche den üblichen Ausnahmen untersteht.

 

Barclays Bank PLC (“Barclays”) und Credit Suisse fungierten im Zusammenhang

mit der Platzierung als Joint Bookrunners, Octavian fungierte als Selling

Agent.

 

 

 

 

Anmerkungen für Herausgeber

 

Über Idorsia

Idorsia AG hat anspruchsvolle Ziele - wir haben mehr Ideen, sehen mehr

Möglichkeiten und möchten mehr Patienten helfen. Um diesen Zielen gerecht zu

werden, möchten wir Idorsia zu Europas führendem biopharmazeutischen

Unternehmen mit einem leistungsfähigen wissenschaftlichen Kern aufbauen.

 

Am Hauptsitz des Unternehmens in der Schweiz - einem Biotech-Knotenpunkt in

Europa - hat sich Idorsia auf die Entdeckung und Entwicklung von

niedermolekularen Wirkstoffen zur Erschliessung neuer Behandlungsmöglichkeiten

spezialisiert. Mit einem umfassenden Portfolio innovativer Arzneimittel in der

Pipeline, einem erfahrenen Team, einem voll funktionalen Forschungszentrum und

einer soliden Bilanzstruktur verfügt Idorsia über ideale Voraussetzungen, um

F&E-Aktivitäten in Geschäftserfolge umzusetzen.

 

Idorsia ist seit Juni 2017 an der SIX Swiss Exchange (Symbol: IDIA) kotiert

und arbeitet mit über 800 qualifizierten Spezialisten an der Umsetzung ihrer

ehrgeizigen Ziele.

 

Für weitere Informationen wenden Sie sich bitte an:

Andrew C. Weiss

Senior Vice President, Head of Investor Relations & Corporate Communications

Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil

+41 (0) 58 844 10 10

www.idorsia.com

 

This press release is for information purposes only and is not intended to

constitute or form a part of any offer or solicitation to purchase or subscribe

for securities in the United States of America, Australia, Canada, Japan, or

any other jurisdiction. The securities mentioned herein have not been and will

not be registered under the US Securities Act of 1933 ('Securities Act') and

may not be offered or sold within the United States of America except pursuant

to an applicable exemption from, or in a transaction not subject to, the

registration requirements of the Securities Act. There will be no public

offering of any of Idorsia’s securities in the United States of America or in

any other jurisdiction.

 

The offers referred to herein, when made in member states of the European

Economic Area ('EEA') and the United Kingdom, is only addressed to and directed

to “qualified investors” within the meaning of Article 2(e) the Prospectus

Regulation ('Qualified Investors'). For these purposes, the expression

'Prospectus Regulation' means Regulation (EU) 2017/1129 of the European

Parliament and of the Council of 14 June 2017 on the prospectus to be published

when securities are offered to the public or admitted to trading on a regulated

market, and repealing Directive 2003/71/EC, and includes any relevant delegated

regulations.

 

For readers in the United Kingdom, this announcement is only being distributed

to and is only directed at Qualified Investors who are (i) outside the United

Kingdom or (ii) investment professionals falling within Article 19(5)

('Investment professionals') of the Financial Services and Markets Act 2000

(Financial Promotion) Order 2005 (the 'Order') or (iii) certain high value

persons and entities who fall within Article 49(2)(a) to (d) ('High net worth

companies, unincorporated associations etc.') of the Order; or (iv) any other

person to whom it may lawfully be communicated (all such persons in (i) to (iv)

together being referred to as 'relevant persons'). The securities are only

available to, and any invitation, offer or agreement to subscribe, purchase or

otherwise acquire such securities will be engaged in only with, relevant

persons. Any person who is not a relevant person should not act or rely on this

document or any of its contents.

 

The offering of the securities in Switzerland is exempt from the requirement

to prepare and publish a prospectus under the Swiss Financial Services Act

('FinSA') because such offering is made to professional clients within the

meaning of the FinSA only. This press release does neither constitute a

prospectus pursuant to the FinSA nor a prospectus within the meaning of art.

652a of the Swiss Code of Obligations or the listing rules of SIX Swiss

Exchange Ltd, and no such prospectus has been or will be prepared for or in

connection with the offering of the securities.

 

Information to Distributors: Solely for the purposes of the product governance

requirements contained within: (a) EU Directive 2014/65/EU on markets in

financial instruments, as amended (“MiFID II”); (b) Articles 9 and 10 of

Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c)

local implementing measures (together, the “MiFID II Product Governance

Requirements”), and disclaiming all and any liability, whether arising in tort,

contract which any “manufacturer” (for the purposes of the MiFID II Product

Governance Requirements) may otherwise have with respect thereto, the Shares

have been subject to a product approval process by each underwriter established

in the EEA or the United Kingdom, which has determined that the Shares are: (i)

compatible with an end target market of retail investors and investors who meet

the criteria of professional clients and eligible counterparties, each as

defined in MiFID II; and (ii) eligible for distribution through all

distribution channels as are permitted by MiFID II (the “Target Market

Assessment”). Notwithstanding the Target Market Assessment, Distributors should

note that: the price of the Shares may decline and investors could lose all or

part of their investment; the Shares offer no guaranteed income and no capital

protection; and an investment in the Shares is compatible only with investors

who do not need a guaranteed income or capital protection, who (either alone or

in conjunction with an appropriate financial or other adviser) are capable of

evaluating the merits and risks of such an investment and who have sufficient

resources to be able to bear any losses that may result therefrom.

 

The Target Market Assessment is without prejudice to the requirements of any

contractual, legal or regulatory selling restrictions in relation to the Offer.

Furthermore, it is noted that, notwithstanding the Target Market Assessment,

the Managers established in the EEA and the United Kingdom will only procure

investors who meet the criteria of professional clients and eligible

counterparties. For the avoidance of doubt, the Target Market Assessment does

not constitute: (a) an assessment of suitability or appropriateness for the

purposes of MiFID II; or (b) a recommendation to any investor or group of

investors to invest in, or purchase, or take any other action whatsoever with

respect to the Shares. Each distributor is responsible for undertaking its own

target market assessment in respect of the Shares and determining appropriate

distribution channels.

 

Barclays and Credit Suisse (“Banks”) are acting exclusively for Idorsia and

no-one else in connection with the offerings. They will not regard any other

person as their respective clients in relation to the offerings and will not be

responsible to anyone other than Idorsia for providing the protections afforded

to their respective clients, nor for providing advice in relation to the

offerings, the contents of this announcement or any transaction, arrangement or

other matter referred to herein. Each of the Banks and their respective

affiliates may have engaged in transactions with, and provided various

commercial banking, investment banking, financial advisory transactions and

services in the ordinary course of their business with the Company and/or its

affiliates for which they would have received customary fees and commissions.

Each of the Banks and their respective affiliates may provide such services to

the Company and/or its affiliates in the future. Barclays is authorised by the

Prudential Regulatory Authority and regulated in the United Kingdom by the

Prudential Regulation Authority and the Financial Conduct Authority.

 

Diese Pressemitteilung kann gewisse zukunftsgerichtete Aussagen betreffend

Idorsia und des Geschäfts von Idorsia enthalten, die durch die Benutzung von

Begriffen wie “schätzt”, “glaubt”, “erwartet”, “könnte”, “wird erwartet”,

“wird”, “wird weitermachen”, “sollte”, “wäre”, “strebt”, “beantragt”, “schwebt”

oder “geht davon aus” oder ähnlichen Ausdrücken sowie durch Diskussionen von

Strategien, Plänen oder Absichten gekennzeichnet sind. Derartige Aussagen

unterliegen gewissen Risiken, Unsicherheiten und andere Faktoren, die die

Resultate, die finanzielle Ausstattung, Performance oder Leistungen von Idorsia

beeinflussen können, so dass diese erheblich von derartigen ausdrücklichen oder

implizit erwähnten zukunftsgerichteten Aussagen abweichen können. Leser sollten

sich daher nicht einfach auf diese Aussagen verlassen, insbesondere nicht im

Zusammenhang mit Verträgen oder einer Investmententscheidung. Idorsia lehnt

jegliche Verpflichtung ab, solche zukunftsgerichteten Aussagen zu

aktualisieren.

 

 

 

Anhang Medienmitteilung PDF

Newsletter

 

Subscribe to our free newsletter and you will receive the latest information about our products and solutions.